

AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

Claims 1-105. (Canceled)

106. (Previously Presented) A method of identifying a compound as a putative anti-prostate cancer or anti-breast cancer agent, the method comprising;

determining the expression of a plexinB1 nucleic acid in a cell or cell lysate in the presence of a test compound as compared with expression of the plexinB1 nucleic acid in the cell or the cell lysate in the absence of the test compound ,

wherein said plexinB1 nucleic acid comprises the plexinB1 coding sequence of AB007867.1 (SEQ ID NO:112) with at least one mutation in the coding region of the nucleic acid selected from the group consisting of C5059T, C5060T, G5074A, A5107G, A5359G, T5401A, G5452A, G5458A, C5468T, A5474G, A5596G, A5653G, C5662T, A5674G, C5713T, T5714C and C5980T, and;

wherein a reduction in expression of the plexinB1 nucleic acid in the cell or cell lysate in the presence of the test compound as compared with expression of the plexinB1 nucleic acid in the cell or the cell lysate in the absence of the test compound identifies the test compound as a putative anti-prostate cancer or anti-breast cancer agent.

Claims 107-108. (Canceled)

109. (Previously Presented) The method according to claim 106, wherein said mutations are selected from the group consisting of C5059T, C5060T, G5074A,

A5359G, T5401A, G5452A, G5458A, C5468T, A5474G, A5596G, A5653G, C5662T, A5674G, C5713T, T5714C and C5980T.

Claim 110. (Canceled)

111. (Previously Presented) The method of claim 106 wherein said at least one mutation is A5653G.

Claims 112-114. (Canceled)

115. (Previously Presented) The method of claim 106 wherein said plexinB1 nucleic acid comprises the plexinB1 coding sequence of AB007867.1 (SEQ ID NO:112) with a mutation A5653G.

116. (Currently Amended) The method of claim 106 wherein said at least one mutation is C5059T ~~T5059G~~ or C5060T.

117. (Previously Presented) The method of claim 106 wherein said putative agent is an anti-breast cancer putative agent and said at least one mutation is G5452A or G5458A and a reduction in expression of the plexinB1 nucleic acid in the cell or cell lysate in the presence of the test compound as compared with expression of the plexinB1 nucleic acid in the cell or the cell lysate in the absence of the test compound identifies the test compound as a putative anti-breast cancer agent.

118. (Previously Presented) The method of claim 106 wherein said putative agent is an anti-prostate cancer putative agent and said at least one mutation is A5653G and a reduction in expression of the plexinB1 nucleic acid in the cell or cell lysate in the presence of the test compound as compared with expression of a of the

WILLIAMSON ET AL
Appl. No. 10/536,804
Attny. Ref.: 620-373
Amendment
February 16, 2010

plexinB1 nucleic acid in the cell or the cell lysate in the absence of the test compound identifies the test compound as a putative anti-prostate cancer agent.